Recommendation IBI-6a(ii): Specialist Hepatology Centre Access
From Infected Blood Inquiry Final Report, published 20 May 2024.
Recommendation
All patients who have contracted hepatitis via a blood transfusion or blood products should receive the following care:
those who have fibrosis should receive the same care
In brief (written by this site)
The Inquiry recommended that transfusion-infected hepatitis patients with fibrosis receive the same care. In May 2025, the UK Government stated that it accepted the recommendation, balancing implementation against National Health Service (NHS) England's role to promote equitable access and clinical guidelines (Cabinet Office response, May 2025). It noted that consultant hepatologists would oversee patient care, while a framework was being developed to identify individuals needing fibrosis staging and a cirrhosis surveillance registry would be introduced (Cabinet Office response, May 2025).
Sources
AI-generated summary of the record on this page, checked by a second model and automatic checks, 1 Oct 2026. The record below is the sources' own words.
About this summary
This recommendation applies across many organisations. The record reflects central policy activity; adoption in individual organisations may vary.
Government response
We accept this recommendation but will balance its implementation against NHS England’s role to promote equitable access for all, the principle that patients should receive the same treatment irrespective of how the disease was acquired, the practicability of implementing different pathways for cohorts of patients, and the latest evidence-based care and clinical guidelines. The Government’s acceptance in full or in principle of 6a) i-v. is contingent on the clarifications received from the Inquiry via correspondence referenced above. DHSC and the NHS are committed to ensuring that all hepatitis patients receive appropriate care, including those patients who contracted hepatitis via a blood transfusion or blood products. All patients will have their care overseen by a consultant hepatologist and NHS England has undertaken an audit of current pathways to satisfy itself that patients with a Hepatitis C diagnosis receive appropriate follow-up and monitoring in line with the relevant National Institute for Health and Care Excellence (NICE) and professional guidance. NHS England will additionally be pro-actively identifying patients with bleeding disorders: who may have been infected with Hepatitis C but never received a fibrosis test, so not had fibrosis staged, and may have been lost to hepatology services. A framework is being developed to define these individuals and enable haemophilia centres to refer forward to local ODN for fibroscan, and assessment for onward monitoring if appropriate; and who are known to have been exposed to ‘factor’ blood products. but not known to have been tested or treated for hepatitis. These patients will be contacted and offered testing and signposted to onward care as appropriate. A new NHS cirrhosis surveillance registry will be introduced to ensure there is a single data source to support the long-term surveillance of patients with cirrhosis. While the numbers of patients who may require testing and follow-up are expected to be small, NHS England is committed to making every effort to ensure all patients with bleeding disorders who may have historically been exposed, have received appropriate testing, treatment and ongoing monitoring.
How this response relates to the recommendation
Site note: The passage quoted here is the response's text for the recommendation's limbs together and does not itself state a position on this limb. The status is taken from the summary table of the same document ("Summary of the Government's response"), which lists "Recommendation 6a) ii)" under "Accepting in principle".
Delivery
No statement on delivery from UK Government has been found in the sources searched (last checked 11 June 2026). This is separate from the response above.
Responsible bodies
Themes and tags
Who has spoken
- UK Government
Response